header art
Dr. Bukreyev

Alexander Bukreyev, Ph.D.

Professor, Galveston National Laboratory; Center for Biodefense and Emerging Infectious Diseases; Department of Pathology

University of Texas Medical Branch
301 University Blvd,
Galveston, TX 77555-0609

Office: (409) 772-2829
Fax: (409) 747-2429
Lab (409) 772-2831
alexander.bukreyev@utmb.edu

Professional Education

Degree Institution Field of Study Graduation Year
MS Pyatigorsk Pharmaceutical Institute, Pyatigorsk, Russia. Pharmacy 1984
PhD State Research Center of Virology and Biotechnology "Vector", Koltsovo, Russia. Molecular Biology 1993

Honors

1994 Personal Russian State Scholarship for Young Outstanding Scientists. Awarded by the Presidium of the Russian Academy of Sciences.
1999 Special Act of Service Award, National Institute of Allergy and Infectious Diseases in Recognition and Appreciation of Special Achievement.
2000 The National Institute of Health Fellows Award for Research Excellence (competitive).
2001, 2002, 2003, 2004, 2005 National Institute of Allergy and Infectious Diseases Staff Recognition Awards in Recognition and Appreciation of Special Achievement.
2006, 2007, 2008 (two awards), 2009 (two awards) National Institute of Allergy and Infectious Diseases Performance Award in Recognition of Special Achievement in Support of the Mission of the National Institute of Allergy and Infectious Diseases.
2009 Convener of the Vaccine and Viral Vectors III Workshop, 28th Annual Meeting of American Society for Virology, University of British Columbia, Vancouver, Canada.
2010 Convener of the Filoviruses Workshop, 29th Annual Meeting of American Society for Virology, Montana State University, Bozeman, Montana.

Professional Affiliations

1996–Present American Society for Virology, Full Member

Research Interests

Filoviruses Ebola and Marburg, the H5N1 highly pathogenic avian influenza viruses, vectored vaccines, mucosal immunization, immuno-pathogenesis, immune response, reverse genetics.

Our group focuses on development of vaccines against highly pathogenic viruses including filoviruses Ebola and Marburg and the H5N1 highly pathogenic avian influenza viruses and on investigation of mechanisms of their high pathogenicity. Our research includes the following specific topics:

  • Development of mucosal respiratory tract vaccines against Ebola virus and the H5N1 highly pathogenic avian influenza virus based on paramyxovirus vectors.
  • Evaluation of the protective efficacy and the immune responses induced by these vaccines in non-human primates.
  • Investigation of mechanisms of protection conferred by these vaccines, including analysis of antibody and cell-mediated responses.
  • Investigation of mechanisms of lymphocyte apoptosis induced by Ebola and Marburg viruses.
  • Investigation of contribution of specific proteins and their functional domains to the high pathogenicity of Ebola and Marburg viruses.
To get insight into these scientific topics, we are using molecular tools, including reverse genetics (i.e. development of genetically modified viruses from the DNA-copies of their genomes) and immunological tools, including multi-color flow cytometry. Our research includes experiments in a BSL-2 lab and in BSL-4 and BSL-3 labs of the Galveston National Laboratory.

Selected Publications (from a total of 56)

ARTICLES IN PEER-REVIEWED JOURNALS:

  1. A. Bukreyev, E. Camargo, and P. Collins. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene (1996). J.  Virol. 70:6634-6641.
  2. B. Beer, R. Kurth, and A. Bukreyev (1999). Characteristics of Filoviridae: Marburg and Ebola Viruses. Review article. Natur Wissenschaften 86:8-17.
  3. A. Bukreyev, S. S. Whitehead, N. Bukreyeva, B. R. Murphy, and P. L. Collins (1999). Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication and yet maintains immunogenicity in mice. Proc. Natl. Acad. Sci. USA 96:2367-2372.
  4. A. Bukreyev, B. R. Murphy, and P. L. Collins (2000). Respiratory syncytial virus can tolerate an tntergenic sequence of at least 160 nucleotides with little effect on transcription or replication in vitro and in vivo. J. Virol. 74:11017-11026.
  5. A. Bukreyev, I. M. Belyakov, J. A. Berzofsky, B. R. Murphy and P. L. Collins (2001). Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 75:12128-12140.
  6. A. Bukreyev and I. Belyakov (2002). Expression of immunomodulating molecules by recombinant viruses: Can the immunogenicity of live virus vaccines be improved? Review article. Expert Rev. Vaccines 1(2):233-245.
  7. A. Bukreyev, M. H. Skiadopoulos, J. McAuliffe, B. R. Murphy, P. L. Collins and A. C. Schmid (2002). More antibody with less antigen: Can immunogenicity of attenuated live virus vaccines be improved? Proc. Natl. Acad. Sci. USA 99:16987-16991. The article was chosen for PNAS press release on 12/09/02.
  8. A. Kotelkin, E. A. Prikhod'ko, J. I. Cohen,  P. L. Collins and A. Bukreyev (2003). Respiratory Syncytial Virus Infection Sensitizes Cells to Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). J. Virol. 77:9156-9172.
  9. A. Bukreyev, E. W. Lamirande, U. J. Buchholz, L. N. Vogel, W. R. Elkins, M. St. Clair, B. R. Murphy, K. Subbarao, and P. L. Collins (2004). Mucosal immunization protects monkeys against SARS coronavirus infection. Lancet. 363(9427):2122-2127. The article was chosen for Lancet press release on 06/23/04 and the NIH press release on 06/24/04.
  10. A. Bukreyev, I. M. Belyakov, G. A. Prince, K. C. Yim, K. K. Harris, J. A. Berzofsky, and P. L. Collins (2005). Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a non-functional cytotoxic T lymphocyte response following primary infection but not following challenge with wild-type virus. J. Virol. 79:9515-9526. The article was chosen for J. Virol. spotlight.
  11. A. Bukreyev, L. Yang, S. R. Zaki, W-J. Shieh,  P. E. Rollin, B. R. Murphy, P. L. Collins, and A. Sanchez (2006). A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal dose Ebola virus challenge. J. Virol. 80:2267-2279.
  12. A. Bukreyev,  M. E. Serra, F. R. Laham, S. R. Kleeberger, P. L. Collins, and F. P. Polack (2006). The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T lymphocyte response despite lacking MHC class I-restricted epitopes. J. Virol. 80:5854-5861. The article was chosen for J. Virol. spotlight.
  13. A. Kotelkin, I. M. Belyakov, L. Yang, J. A. Berzofsky, P. L. Collins, and A. Bukreyev (2006). The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T cell response as a consequence of suppressing the type I interferon response. J. Virol 80:5958-5967.
  14. A. Bukreyev, M. H. Skiadopoulos, B. R. Murphy, and P. L. Collins. (2006). Paramyxoviruses as vaccine vectors. Review. J. Virol. 80:10293-10306.
  15. A. Bukreyev, P. E. Rollin, M. Tate, L. Yang, S. R. Zaki, W.-J. Shieh, B. R. Murphy, P. L. Collins, and A. Sanchez (2007). Intranasal vaccination with a paramyxovirus-vectored vaccine protect primates against challenge with Ebola virus. J. Virol. 81:6379-6388.  
  16. J. DiNapoli, A. Kotelkin, L. Yang, B. R. Murphy, S. Samal, P. L. Collins, and A. Bukreyev (2007). Intranasal immunization of primates with Newcastle disease virus expressing the severe acute respiratory syndrome associated coronavirus (SARS-CoV) spike glycoprotein (S) elicits protection against SARS-CoV challenge. Proc. Natl. Acad. Sci. USA 104(23):9788-9793.
  17. J. M. DiNapoli, L. Yang, A. Suguitan Jr., S. Elankumaran, B. R. Murphy, S. K. Samal, P. L. Collins, and A. Bukreyev (2007). Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces high titer serum neutralizing antibodies against highly pathogenic avian influenza virus. J. Virol. 81(21):11560-11568. The article was chosen for American Society for Microbiology press release in November 2007.
  18. S. Munir, C. Luongo, C. Le Nouen, U. J. Buchholz, P. L. Collins, and A. Bukreyev (2008). Non-structural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J. Virol. 82 (17):8780-8796.
  19. A. Bukreyev, L. Yang, J. Fricke, L. Cheng, J. M. Ward, B. R. Murphy, and P. L. Collins (2008). The secreted form of the G glycoprotein of respiratory syncytial virus helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects of Fc receptor-bearing leucocytes. J. Virol. 82 (24):12191-12204.
  20. J. DiNapoli, B. Nayak, L. Yang, B. W. Finneyfrock, A. Cook, H. Anderson, F. Torres-Velez, B. Murphy, S. Samal, P. Collins, and A. Bukreyev (2010). Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84 (3):1489-1503.

NIH Biosketch

UTMB | Search | Directory | Toolbox | News | Jobs | Contact | Site Map | Site Policies and required links

This site published by John Helms and Steve Schuenke for The Department of Pathology
Copyright © The University of Texas Medical Branch. Please review our site policies and required links